Sunday, 1 Jun 2025
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • DMCA
Subscribe
Brinks Report
  • Featured
  • Money Matters
  • Business
  • IPL
  • Technology
  • Automobile
  • Entertainment
  • Sports
  • More
    • People
    • World
    • Health and Wellness
    • Horoscope
  • Today’s News
  • 🔥
  • World
  • Business
  • Economy
  • Technology
  • Automobile
  • IPL
  • People
  • Sports
  • IPL 2025
  • Entertainment
Font ResizerAa
Brinks ReportBrinks Report
Search
  • Featured
  • Money Matters
  • Business
  • IPL
  • Technology
  • Automobile
  • Entertainment
  • Sports
  • More
    • People
    • World
    • Health and Wellness
    • Horoscope
  • Today’s News
Have an existing account? Sign In
Follow US
© 2024-2025 Brinks Report. All content, including text, images, and other media, is copyrighted.
Brinks Report > Blog > World > New Hope for Cancer Patients! Zydus Lifesciences’ Apalutamide Tablets Approved by USFDA
World

New Hope for Cancer Patients! Zydus Lifesciences’ Apalutamide Tablets Approved by USFDA

Ankita Das
Last updated: March 19, 2025 10:21 am
Ankita Das
Share
Zydus lifesciences gets usfda nod for apalutamide tablets
SHARE
Trulli

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to produce and sell Apalutamide tablets (60 mg) in the U.S. Apalutamide is a medicine used to treat prostate cancer that has spread but is still responsive to hormone therapy.

Contents
Growing Portfolio and AchievementsStrong Financial Growth

The tablets will be made at Zydus Lifesciences’ Special Economic Zone (SEZ) facility in Ahmedabad. As per IQVIA MAT data from January 2025, Apalutamide tablets generated sales of around $1.1 billion in the U.S.

Trulli

Growing Portfolio and Achievements

With this approval, Zydus Lifesciences now has 420 approved medicines and has submitted 483 applications to the USFDA since it started filing in 2003-04. This milestone further strengthens the company’s position in the global pharmaceutical industry, particularly in generic and specialty drugs.

Strong Financial Growth

Zydus Lifesciences, a global healthcare company focused on innovation, reported a solid financial performance in Q3 FY25. The company’s net profit jumped 29.62% year-on-year (YoY) to ₹1,023.5 crore, up from ₹789.6 crore in Q3 FY24. Revenue from operations also increased 16.96% YoY, reaching ₹5,269.1 crore during the quarter.

Following the USFDA approval news, Zydus Lifesciences’ stock price rose 0.57% to ₹908.25 on the Bombay Stock Exchange (BSE), reflecting investor confidence in its growth and regulatory success.

Zydus Lifesciences continues to expand its presence in the global pharmaceutical market. This latest USFDA approval reinforces the company’s commitment to delivering affordable and effective healthcare solutions worldwide.

Image Slider
Image 1 Image 2 Image 3
TAGGED:ApalutamideHealthcarePharmaNewsProstateCancerUSFDAApprovalZydusLifesciences
Share This Article
Facebook Whatsapp Whatsapp Copy Link Print
What do you think?
Love0
Sad0
Happy0
Joy0
Sleepy0
Angry0
Surprise0
Previous Article Why tata power, hdfc bank, and ntpc are topping analysts' 'buy' lists Why Tata Power, HDFC Bank, and NTPC Are Topping Analysts’ ‘Buy’ Lists
Next Article Nifty on fire: will the index smash through 23,000 today? Nifty on Fire: Will the Index Smash Through 23,000 Today?
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Your Trusted Source for Accurate and Timely Updates!

Brink’s Report delivers fresh, unbiased, and engaging content across politics, business, tech, entertainment, and more. From breaking news to deep dives, we keep you informed—and intrigued—with accurate reporting and diverse perspectives. Explore the world, one story at a time.
FacebookLike
XFollow
RSS FeedFollow
Ad image

You Might Also Like

China's exports grow 8% in april, beating expectations
World

China’s exports grew a higher than expected 8% in April as new US tariffs took effect

By
Ankita Das
Harvard university
World

“No Grants Without Obedience”: Trump Blocks $2.2B to Harvard University in Campus Crackdown

By
Dolon Mondal
Fed rate cut depends on us economy’s weakness
WorldEconomy

Fed May Cut Interest Rates Soon – But Only If the US Economy Slows Down!

By
Ankita Das
Monday 17 march 2025 15
World

Massive Fire at North Macedonia Nightclub Killed at Least 50 People

By
Ankita Das
Ad image

About US


Brink’s Report delivers fresh, unbiased, and engaging content across politics, business, tech, entertainment, and more. From breaking news to deep dives, we keep you informed—and intrigued—with accurate reporting and diverse perspectives. Explore the world, one story at a time.

Top Categories
  • World
  • Business
  • Economy
  • Technology
Usefull Links
  • Contact Us
  • About Us
  • Privacy Policy
  • DMCA

© 2024-2025 Brinks Report. All content, including text, images, and other media, is copyrighted.